Business ❯ Healthcare ❯ Pharmaceuticals

Drug Pricing

Weight-loss Drugs Medicare Negotiations Pfizer 340B Program Consumer Access Zepbound Weight Loss Drugs Obesity Drugs Rebates Subscription Models Mark Cuban Major Pharmaceutical Companies Sanofi Agreement Market Competition Eli Lilly and Novo Nordisk Affordability Solutions Market Regulations US Policy Pharmacy Benefit Managers Cost Reduction Access Programs Prescription Drug Platforms E-commerce Government Regulations Ozempic and Wegovy Wegovy Generic Drugs 340B Drug Pricing Program Novo Nordisk Investment Strategies Compounded Medications R&D Funding U.S. Policies Medicaid Policies Negotiation Strategies Insulin Pricing

Supreme Court Rejects Drugmakers’ Appeals Over Medicare Price Talks

The move preserves rulings that back the Inflation Reduction Act program, letting new rounds of negotiated discounts proceed.

AstraZeneca Tops Q1 Forecasts, Reaffirms 2026 Outlook as Oncology Fuels Growth

Mark Cuban Says He Won’t Back Another Kamala Harris Run

GSK Gains After Cramer Endorsement as Company Pushes Into Weight-Loss Drugs

CVS, FTC Reach Proposed Settlement Over Insulin Pricing

Analyses Find Limited Savings as TrumpRx Reaches 54 Drugs

Novo Nordisk to Cut U.S. List Prices for Wegovy, Ozempic and Rybelsus to $675 in 2027

FTC Proposes Consent Order With Express Scripts to Overhaul Insulin Pricing Incentives

Eli Lilly’s Q4 Beat and Bullish Outlook Give Way to Stock Drop on Low-Cost GLP-1 Pills

Cigna’s Evernorth to End Rebates for Many Plans, Shift to Point-of-Sale Pricing and Cost-Plus Pharmacy Pay

EVERSANA, Waltz Health Announce $6 Billion Merger to Build Tech-Driven Drug Access Platform